BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23307043)

  • 1. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer.
    Nouso K; Amano M; Ito YM; Miyahara K; Morimoto Y; Kato H; Tsutsumi K; Tomoda T; Yamamoto N; Nakamura S; Kobayashi S; Kuwaki K; Hagihara H; Onishi H; Miyake Y; Ikeda F; Shiraha H; Takaki A; Nakahara T; Nishimura S; Yamamoto K
    J Gastroenterol; 2013 Oct; 48(10):1171-9. PubMed ID: 23307043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas.
    Akimoto Y; Nouso K; Kato H; Miyahara K; Dohi C; Morimoto Y; Kinugasa H; Tomoda T; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Okada H; Amano M; Nishimura S; Yamamoto K
    Pancreatology; 2015; 15(4):432-8. PubMed ID: 26052067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of a serum glycome analysis in patients with colorectal cancer.
    Takei D; Harada K; Nouso K; Miyahara K; Dohi C; Matsushita H; Kinugasa H; Hiraoka S; Nishimura SI; Okada H
    J Gastroenterol Hepatol; 2022 Apr; 37(4):727-733. PubMed ID: 35064597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis.
    Miyahara K; Nouso K; Saito S; Hiraoka S; Harada K; Takahashi S; Morimoto Y; Kobayashi S; Ikeda F; Miyake Y; Shiraha H; Takaki A; Okada H; Amano M; Hirose K; Nishimura S; Yamamoto K
    PLoS One; 2013; 8(10):e74861. PubMed ID: 24116015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
    Miyahara K; Nouso K; Morimoto Y; Kinugasa H; Kato H; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Nakahara T; Miura Y; Asada H; Amano M; Nishimura S; Yamamoto K
    Pancreas; 2015 May; 44(4):551-6. PubMed ID: 25875794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of serum N-glycan profile in patients with autoimmune pancreatitis.
    Tomoda T; Nouso K; Kato H; Miyahara K; Dohi C; Morimoto Y; Kinugasa H; Akimoto Y; Matsumoto K; Yamamoto N; Noma Y; Horiguchi S; Tsutsumi K; Amano M; Nishimura S; Yamamoto K
    Pancreatology; 2016; 16(1):44-51. PubMed ID: 26723536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of N-glycan profiles in patients with chronic hepatitis and hepatocellular carcinoma.
    Miyahara K; Nouso K; Dohi C; Morimoto Y; Kinugasa H; Wada N; Takeuchi Y; Kuwaki K; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Amano M; Nishimura SI; Yamamoto K
    Hepatol Res; 2015 Sep; 45(9):986-993. PubMed ID: 25495282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers.
    Nakano M; Nakagawa T; Ito T; Kitada T; Hijioka T; Kasahara A; Tajiri M; Wada Y; Taniguchi N; Miyoshi E
    Int J Cancer; 2008 May; 122(10):2301-9. PubMed ID: 18214858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women.
    Gebrehiwot AG; Melka DS; Kassaye YM; Gemechu T; Lako W; Hinou H; Nishimura SI
    BMC Cancer; 2019 Jun; 19(1):588. PubMed ID: 31208374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma.
    Hamfjord J; Saldova R; Stöckmann H; Sandhu V; Bowitz Lothe IM; Buanes T; Lingjærde OC; Labori KJ; Rudd PM; Kure EH
    J Proteome Res; 2015 Dec; 14(12):5144-56. PubMed ID: 26515733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isomer-specific profiling of N-glycans derived from human serum for potential biomarker discovery in pancreatic cancer.
    Liu Y; Wang C; Wang R; Wu Y; Zhang L; Liu BF; Cheng L; Liu X
    J Proteomics; 2018 Jun; 181():160-169. PubMed ID: 29674015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis.
    Yamasaki Y; Nouso K; Miyahara K; Wada N; Dohi C; Morimoto Y; Kinugasa H; Takeuchi Y; Yasunaka T; Kuwaki K; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Iwasaki Y; Amano M; Nishimura S; Yamamoto K
    J Gastroenterol Hepatol; 2015 Mar; 30(3):528-34. PubMed ID: 25168691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of IgG N-glycome profile in colorectal cancer progression by MALDI-TOF-MS.
    Liu S; Cheng L; Fu Y; Liu BF; Liu X
    J Proteomics; 2018 Jun; 181():225-237. PubMed ID: 29698801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
    Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
    Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of serum N-glycan profiling as a diagnostic and prognostic biomarker in germ-cell tumors.
    Narita T; Hatakeyama S; Yoneyama T; Narita S; Yamashita S; Mitsuzuka K; Sakurai T; Kawamura S; Tochigi T; Takahashi I; Nakaji S; Tobisawa Y; Yamamoto H; Koie T; Tsuchiya N; Habuchi T; Arai Y; Ohyama C
    Cancer Med; 2017 Apr; 6(4):739-748. PubMed ID: 28317343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
    Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
    Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel glycan biomarkers for the detection of lung cancer.
    Arnold JN; Saldova R; Galligan MC; Murphy TB; Mimura-Kimura Y; Telford JE; Godwin AK; Rudd PM
    J Proteome Res; 2011 Apr; 10(4):1755-64. PubMed ID: 21214223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of Serum N-glycan Profiling as a Diagnostic Biomarker in Urothelial Carcinoma.
    Oikawa M; Hatakeyama S; Yoneyma T; Tobisawa Y; Narita T; Yamamoto H; Hashimoto Y; Koie T; Narita S; Sasaki A; Tsuchiya N; Habuchi T; Takahashi I; Nakaji S; Ohyama C
    Eur Urol Focus; 2018 Apr; 4(3):405-411. PubMed ID: 28753809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome.
    Haakensen VD; Steinfeld I; Saldova R; Shehni AA; Kifer I; Naume B; Rudd PM; Børresen-Dale AL; Yakhini Z
    Mol Oncol; 2016 Jan; 10(1):59-72. PubMed ID: 26321095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer.
    Ishibashi Y; Tobisawa Y; Hatakeyama S; Ohashi T; Tanaka M; Narita S; Koie T; Habuchi T; Nishimura S; Ohyama C; Yoneyama T
    Prostate; 2014 Nov; 74(15):1521-9. PubMed ID: 25154914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.